1. Home
  2. PLBC vs CLLS Comparison

PLBC vs CLLS Comparison

Compare PLBC & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plumas Bancorp

PLBC

Plumas Bancorp

HOLD

Current Price

$62.33

Market Cap

426.2M

Sector

Finance

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$1.53

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBC
CLLS
Founded
1980
1999
Country
United States
France
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
426.2M
394.4M
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
PLBC
CLLS
Price
$62.33
$1.53
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$57.67
$8.33
AVG Volume (30 Days)
34.4K
145.7K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
2.60%
N/A
EPS Growth
N/A
N/A
EPS
2.79
N/A
Revenue
N/A
N/A
Revenue This Year
$25.59
N/A
Revenue Next Year
$5.15
$0.98
P/E Ratio
$22.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$39.89
$1.25
52 Week High
$64.00
$5.48

Technical Indicators

Market Signals
Indicator
PLBC
CLLS
Relative Strength Index (RSI) 53.23 22.48
Support Level $60.00 N/A
Resistance Level $63.74 $3.47
Average True Range (ATR) 1.23 0.22
MACD -0.04 -0.22
Stochastic Oscillator 59.57 11.89

Price Performance

Historical Comparison
PLBC
CLLS

About PLBC Plumas Bancorp

Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: